Skip to main content

Table 1 Effects of various inhibitors on LPS-induced bronchoconstriction in perfused rat lung

From: Cyclooxygenase-2-Dependent Bronchoconstriction in Perfused Rat Lungs Exposed to Endotoxin

Pretreatment LPS n TV (ml) CL(ml/cm H2O) (RL cm H2O-sec/ml)
19 1.38 ± 0.23 0.16 ± 0.04 0.30 ± 0.04
LPS 24 0.44 ± 0.17a 0.05 ± 0.02a 0.65 ± 0.26a
WEB-2086 LPS 4 0.34 ± 0.11a 0.04 ± 0.03a 0.66 ± 0.29a
MK-571 LPS 3 0.39 ± 0.08a 0.03 ± 0.03a 0.83 ± 0.23a
AA-861 LPS 5 0.35 ± 0.12a 0.05 ± 0.01a 0.56 ± 0.30a
BM-13177 LPS 6 1.17 ± 0.33 0.16 ± 0.07 0.32 ± 0.05
ASA LPS 4 1.36 ± 0.39 0.18 ± 0.07 0.31 ± 0.04
CGP-28238 LPS 3 1.16 ± 0.29 0.24 ± 0.05 0.27 ± 0.04
Dexamethasone LPS 3 1.57 ± 0.56 0.26 ± 0.10 0.25 ± 0.03
  1. Tidal volume (TV), pulmonary compliance (CL) and pulmonary resistance (RL) 110 min after addition of vehicle, LPS or LPS plus various inhibitors. Ten minutes prior to injection of LPS (50 µ/ml), lungs were pretreated with the PAF-receptor antagonist WEB-2086 (66 µM), the leukotriene receptor antagonist MK-571 (10 µM), the 5-lipoxygenase inhibitor AA-861 (10 µM), the TX receptor antagonist BM-13177 (20 µM), the unspecific cyclooxygenase inhibitor acetyl salicylic acid (ASA, 275 µM) or the specific cyclooxygenase-2 inhibitor CGP-28238 (1 µM). Dexamethasone (10 µM) was administered 30 min before injection of LPS. Data are expressed as means ± SD. ap < 0.05 against control.